Respiratory Function at 3 Months After Hospital Discharge in Critically Ill Patients With Covid-19

doi:10.21203/rs.3.rs-2613665/v1

Download PDF

Research Article

Respiratory Function at 3 Months After Hospital Discharge in Critically Ill Patients With Covid-19

https://doi.org/10.21203/rs.3.rs-2613665/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this latest preprint version

Background: Up to 20% of patients with COVID-19 get critically ill and require intensive care unit (ICU)admission. At hospital discharge, most patients still have physical and mental limitations, which affect their quality of life. Pulmonaryfunctional alterations in patients with COVID-19 vary from the absence of functional abnormalities to restrictive and diffusion impairments. We aimed to describe pulmonary function abnormalities as well as their impact on the 6-minute walk test (6 MWT) and SF-36 physical component summary (PCS) score in patients with COVID-19 at ≥ 3 months after hospital discharge.

Methods: Weincluded 65 patients aged ≥ 18 years with severe COVID-19 confirmed throughreal-time reverse transcriptase-polymerase chain reaction andadmitted to the ICU between April 2020 and October 2021. Patients were evaluated at ≥ 3 months after hospital discharge using the 6 MWT, pulmonary function tests (PFTs), and the PCS score.

Results: Among the included patients, 27patients had abnormal PFT findings, 21 (32.3%) had forced vital capacity < 80%, 17 (26.1%) had forced expiratory volume in 1 s< 80%, and 4 (6.1%) had a maximal mid-expiratory flow< 65%. Compared with patients without abnormal PFT findings, patientswith abnormal PFT findings were older and had significantlyhigher ferritin levels. There were no significant between-group differences ininvasive and noninvasive respiratory support, mechanical ventilation duration, vasopressor use,and renal replacement therapy. However, compared with patients with normalPFT findings, patients with abnormal PFT findings showed asignificantly lower 6-MWT score [78% (0.0–92) vs.95% (75–100), p = 0.01] and worse PCS scores [39.4 (32.1–51.3) vs. 52.0 (47.4–57.3), p = 0.007]. There was an independent association between the PCS scores and PFT findings.

Conclusions: We found that a significant proportion of patients present pulmonary functional alterations ≥ 3 months after discharge from the hospital after treatment forsevere COVID-19; further, these alterations affectphysical functional capacity and quality of life.

Trial registration: The trial protocol was approved by the Research Ethics Committee of the Hospital Sao Domingos (Number 5.403.663) in May 12, 2022 and registered in clinical trials. Gov(NCT05249842), February 22, 2022.

SARS-CoV-2

Post-COVID

Pulmonary function test

Follow-up

Physical component summary

6-minute walk test

The coronavirus 2019 (COVID-19) pandemic has affected > 600 million people worldwide, resulting in ≥ 6 million deaths (https:coronavirus.jhu.edu/map.html). Although its acute phase has been clinically characterized [1, 2], the clinical evolution of patients with COVID-19 after hospital discharge remains unclear. Specifically, there are limited available data from follow-up studies. Preliminary studies have indicated that a substantial proportion of patients present with symptoms persisting for several months [3, 4]. Some patients present with organ damage, especially in the lungs [5, 6]. Recent studies have described the frequency and severity of pulmonary structural and functional changes after discharge in hospitalized patients with COVID-19 who received invasive and non-invasive respiratory support. These studies have demonstrated that a considerable proportion of these patients present constitutional manifestations [7, 8] and tomographic alterations [7, 9]. However, pulmonary function tests (PFTs) in the patients either reveal normal findings or restrictive alterations and gas exchange alterations indicated by reduced lung diffusion capacity for carbon monoxide (DLCO). Regarding physical performance, studies have reported changes in the 6-minute walk test (6 MWT) scores [9]. There has been increasing interest in the clinical manifestations of COVID-19 at least 3 months after disease onset, which is termed as post-COVID-19 syndrome [10], given the high proportion of patients who remain with permanent sequelae. Since the lung is the main target organ of the disease in the acute phase, elucidating medium- to long-term pulmonary functional changes and their effects on the physical quality of life could inform patient rehabilitation programs [11, 12].

Accordingly, we aimed to determine the prevalence of restrictive, obstructive, and small airway alterations in survivors of severe COVID-19 at least 3 months after hospital discharge. Further, we aimed to examine their spirometry patterns using the 6-MWT and physical component summary (PCS) of the SF-36 quality-of-life instrument.

This retrospective observational cohort study included 65 patients aged ≥ 18 years with severe COVID-19 confirmed using real-time reverse transcriptase-polymerase chain reaction and admitted to a 35-bed intensive care unit of a tertiary hospital between April 1, 2020, and October 31, 2021. We excluded pregnant or breastfeeding women, patients receiving palliative care, patients with chronic obstructive pulmonary disease, and patients with symptomatic asthma. Upon hospital discharge, patients were invited for evaluation in our multidisciplinary follow-up clinic after 3 months. Here, the patients were evaluated using the 6-MWT, PFTs, and the PCS score for quality of life. The trial protocol was approved by the Research Ethics Committee of the Hospital Sao Domingos (Number 5.403.663) and registered in clinical trials. Gov (NCT05249842).

Data were obtained from the electronic medical records of the hospital. The demographic and clinical characteristics included age, sex, Simplified Acute Physiology Score 3 score, and comorbidities. The clinical and laboratory data upon ICU arrival included PaO2/ FIO2, blood count, C-reactive protein, D-dimer, ferritin, fibrinogen, and lactic dehydrogenase. The drug interventions included corticosteroids, heparin, and tocilizumab. Further, we collected data regarding the characteristics of invasive and non-invasive respiratory support, use of the prone position, and vasoactive drugs. Additionally, we collected data regarding the main complications, acute kidney injury requiring hemodialysis, secondary infectious complications, and clinical outcomes. Acute renal injury was characterized using the Kidney Disease Improving Global Outcomes score criteria [13]. The presence of infectious bacterial or fungal complications was determined by the attending physician based on the laboratory (mainly procalcitonin), microbiological, and imaging data. The PFTs included forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), FEV1/FVC ratio, and maximal mid-expiratory flow (MMEF) using a spirometer Spirobank II (MIR, Italy). The standardization and categorization of functional changes were based on Brazilian guidelines for PFTs (14).

Statistical analysis

Categorical variables are reported as frequencies and proportions. Normally and non-normally distributed quantitative variables are presented as mean (standard deviation) and median (interquartile range), respectively. We performed between-group comparisons of categorical variables using the χ² test or Fisher’s exact test, as appropriate. For quantitative variables, the non-parametric Mann-Whitney U test or Student’s t-test was used.

A multiple logistic regression model was used to identify clinical characteristics related to pulmonary functional changes. Variables with p < 0.20 in the unadjusted analysis were included in the model. Additionally, variables with p < 0.05 in the adjusted analysis were considered significant.

Statistical significance was set at P < 0.05. Statistical analyses were performed using the R software version 4.0.2 (R Core Team, 2017).

From April 1, 2020, to October 31, 2021, 689 patients were admitted to the ICU for COVID-19 at the Hospital São Domingos. Moreover, 358 and 332 patients were discharged from the ICU and hospital, respectively. Among them, 65 discharged patients were evaluated at the hospital’s ICU follow-up clinic within a median post-discharge period of 146 (120–183) days (Fig. 1). The median age of the enrolled participants was 50 years (43–60 years),

FIGURE 1 HERE

with 36 (55.3%) men and 29 (44.6%) women. The most common comorbidity was hypertension (22 patients, 33.8%), followed by diabetes (13 patients, 20%) and obesity (9 patients, 13.8%). In addition, 45 (69.2%) patients underwent invasive mechanical ventilation. Furthermore, 27 (41.5%) patients had abnormal PFT findings as follows: FVC < 80% in 21 (32.3%) patients, FEV1 < 80% in 17 (26.1%) patients, FEV1 / FVC < 0.7 in 0 patients, and MMEF < 65% in 4 (6.1%) patients. Table 1 shows the comparisons of the demographics, clinical severity, laboratory data, therapeutic interventions, and outcomes between patients with normal and abnormal PFT findings (n = 38 and n = 27, respectively). Compared with

Table 1

Baseline characteristics and outcomes
	Normal RFT N = 38	Abnormal RFT N = 27	p
Age, y Median (IQR)	54 (41.5–63.0)	48 (44–54)	0.04
Males, n (%)	21 (55.2)	15 (55.5)	0.23
SAPS 3 score Median (IQR)	51 (45–62)	50 (46–60)	0.35
Comorbidities (n) Hypertension Diabetes Obesity	15 7 4	7 6 5	0.13
Laboratory data at admission, Median (IQR) D-dimer, mg/L Ferritin, ng/ml Fibrinogen, mg/dL PaO2/FIO2	1410 (710–8355) 1358 (635–1807) 612 (521–734) 172 (130–222)	3240 (1200–8470) 2000 (886–3000) 662 (499–799) 195 (129–256)	0.11 0.02 0.33 0.47
Life-sustaining support during ICU stay Nasal O2/Venturi Non invasive ventilation Invasive ventilation Duration of IMV, d Median (IQR) Vasopressors, n (%) RRT, n (%) Corticosteroids, n (%)	5 9 24 12 19 4 24	2 4 21 10 18 7 22	0.65 0.76 0.67 0.61 0.22 0.86
ICU LOS, d Median (IQR)	13 (7–13)	5 (2–7)	0.07
Hospital LOS, d Median (IQR)	25 (18–39)	34 (17–68)	0.10
Pulmonary Function Tests FVC < 80%, n (%) FEV1 < 80%, n (%) FEV1 / FVC < 0.7, (n %) MMEF < 65%, n (%)		21 (32.3%) 17 (26.1%) 0 (0%) 4 (6.1%)
Length of time to follow-up ICU discharge/follow up, Evaluation, d Median (IQR)	158 (140–187)	146 (118–195)	0.08
Hospital Discharge/Follow-up Evaluation, d Median (IQR)	155 (134–176)	138 (93–185)	0.04
6-MWT (%)	95 (75–100)	78 (0.0–92)	0.01
PCS score Median (IQR)	52.0 (47.4–57.3)	39.4 (32.1–51.3)	0.007
SAPS 3 Simplified Acute Physiology Score, PFT pulmonary function tests, 6-MWT 6-minute walk test, PCS physical component summary.

Table 1 HERE

patients without abnormal PFT findings, patients with abnormal PFT findings were older and had significantly higher ferritin levels [1358 (635–1807) vs. 2000 (886–3000), p = 0.02]. There were no significant between-group differences in invasive and noninvasive respiratory support, mechanical ventilation duration, vasopressor use, and renal replacement therapy. However, compared with the group with normal PFT findings, the group with abnormal PFT findings showed a significantly lower 6-MWT score [78% (0.0–92) vs. 95% (75–100), p = 0.01] and worse PCS scores [39.4 (32.1–51.3) vs. 52.0 (47.4–57.3), p = 0.007].

In the logistic regression model of PFT after 4 months with adjustment for independent covariates, multivariate analysis showed statistical significance for the PCS (p = 0.01) and a tendency toward significance for the 6-MWT (p = 0.09).

In our study, 41.5% of the patients presented abnormal PFT findings within a median post-discharge period of 4.8 months; additionally, these alterations affected the quality of life as indicated by the 6 MWT and PCS scores. Multivariate analysis revealed an independent association between lower PCS scores and abnormal PFT findings.

Several studies have examined lung functional changes in hospitalized patients with COVID-19 of varying severities. In a Spanish multicenter study, Blanco et al. [15] analyzed 100 patients with mild/moderate or severe COVID-19; however, they excluded patients undergoing mechanical ventilation. The patients were evaluated within a median duration of 3 months after the onset of symptoms, with the PFTs only revealing changes in the DLCO. Fortini et al. [8] analyzed 59 patients who were hospitalized in non-intensive wards after a median post-discharge period of 4 months. They observed abnormal PFT findings, with the most common being a reduction in the DLCO (37% of the patients). Although they described the persistence of symptoms, they did not objectively analyze aspects regarding the quality of life at 4 months after discharge. Polese et al. [7] analyzed changes in PFT findings in 41 patients hospitalized with severe COVID-19 within 36 days after the onset of symptoms. They observed changes in the FVC and DLCO in > 50% and 79% of the patients, respectively. Further, 45% of the patients showed a significant reduction in the distance covered in the 6 MWT. Van Gessel et al. [9] evaluated 48 hospitalized patients with severe COVID-19 who underwent invasive mechanical ventilation 3 months after hospital discharge. They observed significant reductions in the total lung capacity and DLCO. Moreover, there was a high proportion of patients with pulmonary fibrosis on the computed tomography scan and a reduction in the distance covered in the 6 MWT. A meta-analysis of respiratory function after COVID-19 infection included seven studies and 380 patients [16]. Among them, two, two, two, and one study performed follow-up assessments at 2 weeks after hospital discharge, 30 days after symptom onset, 1 month after hospital discharge, and 3 months after hospital discharge, respectively. DLCO, restrictive, and obstructive changes were identified in 39%, 15%, and 7%, respectively. Early evaluation may impede the accuracy of functional diagnosis since we cannot determine the extent of post-infection sequelae and acute inflammation. The British Thoracic Society recommends evaluation using PFTs ≥ 3 months after discharge [17].

The present study assessed the prevalence of small airway changes using the MMEF test, with four patients (6.1%) having values < 65%. There have been inconsistent reports regarding small airway changes in patients with COVID-19. Lindahl et al. [18] analyzed 20 patients with severe COVID-19 at 3 and 6 months after hospital discharge through impulse oscillometry and observed no small airway changes. Cho et al. [19] analyzed 100 patients with varying degrees of COVID-19 severity and found that 52% of patients showed tomographic changes suggestive of small airway involvement. Future multicenter prospective studies are warranted.

Although the clinical manifestations of the acute COVID-19 phase and each evolutionary phase of the disease are well established, its long-term effects remain unclear. Recent studies have demonstrated that some patients with COVID-19 present with clinical manifestations that last for up to 4–12 weeks (symptomatic COVID-19) and > 12 weeks (post-COVID-19 syndrome) after the onset of symptoms. In our study, we observed changes in the PFT, 6 MWT, and PCS scores, which can be described as post-COVID syndrome, in 41.5% of patients. Huang et al. [20] analyzed 1733 patients at 6 months after symptom onset and found that 76% of patients had at least one symptom, with the most common being muscle weakness; however, others presented with anxiety, depression, cognitive changes, and reduced 6 MWT scores. Regarding pulmonary functional alterations, the most common alterations were observed in the carbon monoxide diffusion test; however, there were abnormal PFT findings that characterized a restrictive disorder.

This study has several limitations. First, this was a retrospective single-center study, which accordingly involves limited volume and quality of information. Second, we did not evaluate the DLCO, which showed the most prevalent alteration in previous studies. Patients with COVID-19 underwent ICU follow-up clinic evaluation by a multidisciplinary evaluation that included physicians, physical therapists, psychologists, and nutritionists. Pulmonary function tests were performed by the physical therapist and evaluated by the pulmonologist. More elaborate tests, including DLCO, were outside the scope of this evaluation. All patients with abnormal PFT results were referred for evaluation and follow-up by the hospital's pulmonology service.

Our findings showed that a significant proportion of patients who are discharged from the hospital after treatment for severe COVID-19 present pulmonary functional alterations at least 3 months after discharge. Moreover, these alterations affect the physical functional capacity and quality of life. Our results support that patients with severe COVID-19 need pos-discharge care. Studies with larger population and longer follow-up are necessary to improve the knowledge about health consequences of COVID-19.

ICU: Intensive Care Unit; 6-MWT: 6-minute walk test; PCS: physical component summary; SF-36: Short form survey for quality of life; PFT: Pulmonary function test; SAPS 3: Simplified acute physiology score version 3; PaO2/FIO2: ratio of arterial oxygen partial pressure (PaO2) to fractional inspired oxygen; KDIGO: Kidney Disease Improving Global Outcomes score criteria; FVC: Forced vital capacity; FEV1= forced expiratory volume in the first second; MMEF: maximal mid-expiratory flow; DLCO: lung diffusion capacity for carbon monoxide.

Ethics approval and consent to participate

The trial protocol was approved by the Research Ethics Committee of the Hospital Sao Domingos (Number 5.403.663) in May 12, 2022 and registered in clinical trials. Gov (NCT05249842), February 22, 2022.

Consent for publication

Not applicable

Availability of data and materials

The dataset used and/or analyzed during the current study are aavailable from the corresponding author on reasonable request

Competing interests

None declared

Funding

None declared

Authors' contributions

Conceptualization (JHCFL, FSTN, SCCS, LF, JRAA); Methodology (JHCLF, SCCS, GBT, LF, JRAA) Data collection and analysis ( JHCLF, GBT, FSTN, AMCS); Original draft preparation (JHCLF, FSTN, SCCS, LF, AMSC); Supervision (JRAA); All authors have read and approved the manuscript.

Acknowledgements

Not applicable

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–20.
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782–93.
Carfì A, Bernabei R, Landi F, Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603–5.
Garrigues E, Janvier P, Kherabi Y, Bot AL, Hamon A, Gouze H, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020;81:e4-6.
Melms JC, Biermann J, Huang H, Wang Y, Nair A, Tagore S, et al. A molecular single-cell lung atlas of lethal COVID-19. Nature. 2021;595:114–9.
Mo X, Jian W, Su Z, Chen M, Peng H, Peng P, et al. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur Respir J. 2020;55:2001217
Polese J, Sant’Ana L, Moulaz IR, Lara IC, Bernardi JM, de Lima ND, et al. Pulmonary function evaluation after hospital discharge of patients with severe COVID-19. Clinics (Sau Paulo) 2021;76:e2848.
Fortini A, Torrigliani A, Sbaragli S, Forte AL, Crociani A, Cecchini P, et al. COVID-19: persistence of symptoms and lung alterations after 3–6 months from hospital discharge. Infection. 2021;49:1007–15.
Gassel RJJ, Bels JLM, Raafs A, van Bussel BCT, van de Poll MCG, Simons SO, et al. High prevalence of pulmonary sequelae at 3 months after hospital discharge in mechanically ventilated survivors of COVID-19. Am J Respir Crit Care Med. 2021;203:371–4.
Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID19 syndrome. Na Med. 2021;27:601–15.
Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220 – 32 (2021).
Esenadagli D, Yilmaz A, Akçay S, Özlü T. Post-COVID syndrome: pulmonary complications. Turk J Med Sci. 2021;51:3359–71.
Clinical Practice Guidelines for Acute Kidney Injury 2012. http://www.kdigo.org/clinical_practice_guidelines/AKI.php.
Diretrizes para testes de função pulmonar. J Bras Pneumol 2002; 28 (Suppl 3).
Blanco JR, Ceballos MJC, Navarro F, Sanjoaquin I, de las Revillas FA, Bernal E, et al. Pulmonary long-term consequences of COVID-19 infections after hospital discharge. Clin Microbiol Infect. 2021;27:892–96.
Torres-Castro R, Castillo LV, Reatay XA, Navarro L, Burgos F, Puppo H, et al. Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis. Pulmonology. 2021;27:328–37.
British Thoracic Society. British Thoracic Society Guidance on Respiratory Follow Up of Patients with a Clinic Radiological Diagnosis of COVID-19 Pneumonia [Internet]. 2020. Available from: https://www.brit-thoracic.org.uk/ document-library/quality-improvement/covid-19/resp-followup-guidance-post-covid-pneumonia/.
Lindahl A, Reijula J, Malmberg LP, Aro M, Vasankari T, Mäkelä MJ. Small airway function in Finish COVID-19 survivors. Respir Res. 2021;22:237.
Cho JL, Villacreses R, Nagpal P, Guo J, Pezzulo AA, Thurman AL, et al. Quantitative chest CT assessment of small airways disease in post-acute SARS-CoV-2 infection. Radiology. 2022;304:185–92.
Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;297:220–32.

No competing interests reported.

Download PDF

Version 1

posted

You are reading this latest preprint version

Respiratory Function at 3 Months After Hospital Discharge in Critically Ill Patients With Covid-19

Status:

Version 1

Abstract

Figures

Background

Methods

Statistical analysis

Results

Discussion

Conclusions

Abbreviations

Declarations

References

Additional Declarations

Status:

Version 1